8:00 am Chair’s Opening Remarks: IPF in a World with COVID-19

  • Fernando Martinez Chief Division of Pulmonary & Critical Care Medicine, Weill Cornell Medicine

What do we Know & What are we Trying to Achieve? Key Pathways, Treatable Traits, Tool Compounds

8:30 am Reviewing Evidence & Understanding of “Anti-Fibrotic” Compounds Clinically: Do we Have “Anti-Fibrotic” Drugs & How are They ‘Anti- Fibrotic”?

  • Cory Hogaboam Professor of Medicine, Cedars-Sinai Medical Center

9:00 am Panel Discussion: Mechanistic Interrogation of Existing Drugs

  • Cory Hogaboam Professor of Medicine, Cedars-Sinai Medical Center
  • Eric White Director, Clinical Development, ILD Therapeutic Area, Boehringer Ingelheim & Adjunct Professor, University of Michigan
  • David Rowlands Associate Director, Respiratory Biology, NIBR

9:30 am Speed Networking

10:15 am
Morning Break & Networking

Preclinical & Early Translational Track

Late Translational & Clinical Track

New Approaches to Fibrosis Biology & Translation

Predicting Mortality with Biomarkers

11.00 Mechanisms of Lung Protection by Innate Immunity Modulators

Andrei Gudkov, Chief Scientific Officer, Genome Protection, Professor of Oncology, Roswell Park Comprehensive Cancer Center

11.00 An Update from PROLIFIC Biomarker Consortium

Peter Schafer, Executive Director, Translational Medicine, Bristol Myers Squibb

11.30 From in vitro to ‘In Matrico’: Human Fibrotic Lung Extracellular Matrix Substrates Increase the Relevance of Cell-Based IPF Models for Anti-Fibrotic Drug Development

John O’Neill, Co-Founder & Chief Scientific Officer, Xylyx Bio

11.30 Session Held by ERT

11.45 Phenotypes, Genotypes, & Subtypes of Fibroblasts in Lung Fibrosis

Dianhua Jiang, Professor of Medicine & Biomedical Sciences, Scientific Director, Pulmonary Fibrosis Research Center, Cedars Sinai Medical Center

11.45 Biomarkers for Managing ILDs

Eric White, Director, Clinical Development, ILD Therapeutic Area, Boehringer Ingelheim & Adjunct Professor, University of Michigan

12:15 pm
Lunch & Networking

Preclinical & Early Translational Track

Late Translational & Clinical Track

Is Pulmonary Fibrosis the Same as Fibrosis, the Same as Fibrosis?

Clinical Trial Endpoints – Old & New

1.30 Inhibition of a Convergent Step in Extracellular Matrix Formation to Reduce Fibrosis

Wolfgang Jarolimek, Head of Drug Discovery, Pharmaxis

1.30 Forced Vital Capacity as a Clinical Trial Endpoint: PROs and CONs

Jack Stauffer, Senior Medical Director, Genentech

2.00 Untangling the Dualistic Components of the RAS (renin–angiotensin system) in Pulmonary Fibrosis – the Ying & Yang

Rohit Batta, Chief Medical Officer, Vicore Pharma

2.00 Quantifying Normal Lung as Surrogate Endpoint in Patients with Pulmonary Fibrosis

Mary Salvatore, Associate Professor, Radiology, Columbia University Medical Center

2.30 Lessons in Biomarkers from Across Fibrosis

Sydney Montesi, Instructor in Medicine, Harvard University

 

2.30 The Utility of PET-based Molecular Imaging in IPF

Tejaswini Kulkarni, Assistant Professor, Pulmonary & Critical Care Medicine, UAB

3:00 pm
Afternoon Break & Networking

Scientific Foundations for the Next Generation of IPF Targets
Interrogation of IPF Pathophysiology to
Advance the Next Generation of Disease Modifying Candidates

3:30 pm How Three Lakes Foundation is Accelerating Therapies for Pulmonary Fibrosis

4:00 pm Implications of the Insights from the IPF Cell Atlas for Drug Development

  • Naftali Kaminski Section Chief, Pulmonary, Critical Care & Sleep Medicine, Yale School of Medicine

4:30 pm The Impact of Nintedanib on the Single Cell Seq Profile of Macrophage Populations

Pulmonary Fibrosis in a World with Covid-19
What New Challenges Relate to the Lung’s Response to Covid-19 &
How do we Utilize Current Understanding & Models to Accelerate this Research

5:00 pm Roundtable Discussions

5:30 pm Feedback Panel on Roundtable Discussions

6:00 pm Scientific Poster Session